Publications by authors named "A Nidegger"
Article Synopsis
- The study aimed to analyze how well biologic drugs (IL-23 and IL-17 inhibitors) work for treating psoriasis in patients aged 65 and older compared to younger patients.
- It found that elderly patients had a higher risk of discontinuing treatment, especially with IL-23 inhibitors, while IL-17 inhibitors didn't show a significant difference.
- Additionally, factors like previous treatments influenced the likelihood of continuing or stopping the medication in elderly patients.
Auto-immune bullous diseases (AIBD) are rare in children. Although their pathogenesis is similar to their adult counterpart, there are differences in the clinical presentation. Moreover certain AIBD prevail at certain ages.
View Article and Find Full Text PDFArticle Synopsis
- The study examines the "drug survival" of several psoriasis treatments, including secukinumab and guselkumab, to compare their effectiveness and predict patient adherence to therapy.
- Researchers analyzed data from nearly 5,000 treatment courses across multiple countries between 2015 and 2021, focusing on patients with moderate to severe psoriasis using various interleukin inhibitors.
- Results indicated that IL-23 inhibitors generally had better drug survival rates after 24 and 36 months compared to IL-17 inhibitors, with specific percentages provided for each drug's effectiveness over time.
Biologics targeting specific cytokines and pathways have revolutionized the management of patients with chronic inflammatory diseases. However, these treatments have their limitations and, surprisingly, can induce novel inflammatory diseases. Here, we present a case of a psoriasis patient developing anti-IL17 induced eczema, an intriguing side effect of IL-17 blockade.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the drug survival rates of the latest biologic agents for moderate-to-severe psoriasis, including ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, and risankizumab, to understand their effectiveness and safety as well as factors influencing patient adherence to treatment.
- Conducted in 16 dermatology centers across several countries, the research analyzed medical records from patients who started these medications between 2012 and 2019, using methods like the Kaplan-Meier estimator for survival analysis.
- Results showed that risankizumab had the highest drug survival rate at 96.4% after 18 months, while secukinumab had the lowest at 79.